Qisi Zhang

Qisi Zhang

Auto-generated profile, based on publicly available information

Qisi Zhang

State key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Chemical Communications
Verified
Journal Article
Open access
PDF file
QZQisi Zhang
Qisi Zhang
CKCyrille S. Kounde
Cyrille S. Kounde
MMMilon Mondal
Milon Mondal
JGJake L. Greenfield
Jake L. Greenfield
JBJennifer Baker
Jennifer Baker
ETEdward W. Tate
Edward W. Tate
A new class of arylazopyrazole photoswitchable PROTACs (AP-PROTACs) enables light-triggered degradation of a specific ensemble of protein kinases.

24 July 2025 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
QZQisi Zhang
Qisi Zhang
LSLonglong Si
Longlong Si

18 March 2026 in Nature Communications
Verified
Journal Article
Open access
JHJiawei Hao
Jiawei Hao
PWPing Wang
Ping Wang
QSQuan Shen
Quan Shen
XXXuetong Xi
Xuetong Xi
LTLe Tong
Le Tong
LSLonglong Si
Longlong Si
The lysosome is a cell’s endogenous machinery responsible for degrading proteins. Here we describe two lysosome-targeting live attenuated vaccine approaches, LYTAR 1.0 and LYTAR 2.0, by harnessing the lysosome to conditionally degrade viral proteins of influenza virus. LYTAR 1.0 incorporates a conditionally removable lysosome-targeting motif at the N- or C-terminus of viral proteins. LYTAR 2.0 allows flexible placement of lysosome-targeting motifs at internal or terminal sites of viral proteins. The resulting lysosome-targeting vaccine strains are attenuated by lysosome-mediated viral protein degradation in conventional cells, while maintaining replication efficiencies comparable to the wild-type virus in producer cell lines. In mouse models, these vaccine candidates are attenuated, induce strong and broad adaptive immune responses, and provide cross-reactive protection against H1N1 and H3N2 influenza viral challenges. This study establishes a lysosome-targeting vaccine platform for developing safe and effective live attenuated vaccines.

28 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJiawei Hao
Jiawei Hao
PWPing Wang
Ping Wang
LLLe Li
Le Li
QWQikai Wang
Qikai Wang
QSQuan Shen
Quan Shen
LSLonglong Si
Longlong Si
Despite existing vaccines, influenza remains a significant public health burden, highlighting the need for vaccine strategies with improved safety and efficacy. Here we develop an autophagy-targeting influenza. A virus as a live attenuated vaccine by harnessing the host cell’s autophagy machinery to manipulate viral protein degradation. The virus is generated by introducing a conditionally removable autophagosome-targeting motif in the viral genome, which enables viral attenuation through autophagy-mediated degradation of the tagged viral protein in conventional cells while permitting efficient viral replication for large-scale manufacturing in engineered cell lines. The engineered virus is highly attenuated in vivo but able to induce robust humoral, mucosal, and cellular immune responses, and provides complete cross-reactive protection against homologous and heterologous viral challenges. Together, this study establishes autophagy-mediated protein degradation as a viable strategy for tuning viral attenuation, which could be adapted for the rational design of live attenuated vaccines against additional pathogens.